Skip to main content
Fig. 8 | Cell Communication and Signaling

Fig. 8

From: Functional signaling test identifies HER2 negative breast cancer patients who may benefit from c-Met and pan-HER combination therapy

Fig. 8

Combination of pan-HER and c-Met inhibitors effectively reduce tumor size in the xenograft model. Activity of c-MET and HER specific antagonists in a HCC1954 a NSG mouse xenograft model. Ten mice cohorts were dosed orally QD for 21 days. Mouse weights (Panels A and C) and tumor size (Panels B and D) were recorded every 3 days

Back to article page

Cell Communication and Signaling

ISSN: 1478-811X